Trial Profile
An open label, multi-center, Phase IV roll-over protocol for patients who have completed a prior global Novartis or Incyte sponsored ruxolitinib (INC424) study or a study of ruxolitinib in combination with panobinostat (LBH589) or siremadlin (HDM201) or rineterkib (LTT462) and are judged by the investigator to benefit from continued treatment
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 22 Apr 2024
Price :
$35
*
At a glance
- Drugs Panobinostat (Primary) ; Ruxolitinib (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 18 Apr 2024 This trial has been completed in Portugal , according to European Clinical Trials Database record.
- 10 Jan 2024 This trial has been completed in Bulgaria, according to European Clinical Trials Database record.
- 12 Dec 2023 This trial has been completed in France, according to European Clinical Trials Database record.